🧫 Experiment Protocol
Validationproposed
SUMMARY
# Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
## Background and Rationale
Alpha-synuclein aggregation represents a central pathological hallmark of Parkinson's disease and related synucleinopathies, yet the fundamental mechanisms governing the transition from functional monomer to pathogenic aggregates remain incompletely understood. While alpha-synuclein's physiological role involves binding to synaptic vesicles through its N-terminal amphipathic helices, the precise molecular e
METHODOLOGY NOTES
**Phase 1: Single-Molecule Biophysics Setup and Protein Preparation (Months 1-2)**
Express and purify recombinant human alpha-synuclein and fluorescently-labeled variants (N-terminal ATTO488, C-terminal ATTO647N) using bacterial expression systems. Prepare synthetic lipid vesicles with varying compositions: pure DOPC, DOPC/DOPS (70:30), DOPC/DOPS/cholesterol (50:30:20), and brain-derived lipid extracts. Set up total internal reflection fluorescence (TIRF) microscopy system with dual-color imaging capability and temperature control. Establish single-molecule FRET (smFRET) assays to monitor conformational changes during membrane binding. Validate protein functionality using thioflavin-T aggregation assays and electron microscopy.
**Phase 2: Membrane Binding Kinetics and Conformational Analysis (Months 3-5)**
Perform single-molecule tracking experiments to measure alpha-synuclein binding kinetics to different membrane compositions. Use smFRET to monitor real-time conformational changes